SYRS Stock Price, Syros Pharmaceuticals Quote, Chart

Market Summary

USD5.45-0.03

Market Closed

-0.55%

SYRS Stock Price

View Fullscreen

SYRS RSI Chart

SYRS Valuation

Market Cap

145.7M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

14.66

Price/Free Cashflow

-1.4

SYRS Price/Sales (Trailing)

SYRS Profitability

Return on Equity

-959.64%

Return on Assets

-107.25%

Free Cashflow Yield

-71.52%

SYRS Fundamentals

SYRS Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

-88.71%

Rev. Growth (Qtr)

-89.73%

SYRS Earnings

Earnings (TTM)

-144.5M

Earnings Growth (Yr)

84.41%

Earnings Growth (Qtr)

94.24%

Breaking Down SYRS Revenue

Last 7 days

9.7%

Last 30 days

6.7%

Last 90 days

-24.1%

Trailing 12 Months

40.8%

How does SYRS drawdown profile look like?

SYRS Financial Health

Current Ratio

3.01

Debt/Equity

1.97

Debt/Cashflow

-3.5

SYRS Investor Care

Shares Dilution (1Y)

29.78%

Diluted EPS (TTM)

-5.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.6M	12.4M	11.2M	9.9M
2022	24.1M	25.2M	23.4M	14.9M
2021	17.5M	19.5M	21.4M	23.5M
2020	3.9M	6.6M	9.9M	15.1M
2019	2.1M	2.2M	2.4M	2.0M
2018	370.0K	745.0K	1.2M	2.0M
2017	684.0K	1.1M	1.4M	1.1M
2016	0	0	0	317.0K
2015	0	0	0	317.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Syros Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	roth david	sold	-51,732	4.95	-10,451	chief medical officer
Apr 02, 2024	roth david	sold	-747	4.9803	-150	chief medical officer
Apr 01, 2024	haas jason	sold (taxes)	-24,227	5.12	-4,732	chief financial officer
Apr 01, 2024	roth david	sold (taxes)	-24,227	5.12	-4,732	chief medical officer
Apr 01, 2024	chee conley	sold (taxes)	-17,920	5.12	-3,500	president & ceo
Apr 01, 2024	simonian nancy a	sold (taxes)	-71,946	5.12	-14,052	-
Apr 01, 2024	stephens kristin	sold (taxes)	-21,596	5.12	-4,218	chief development officer
Mar 31, 2024	stephens kristin	acquired	-	-	13,666	chief development officer
Mar 31, 2024	haas jason	acquired	-	-	15,333	chief financial officer
Mar 31, 2024	roth david	acquired	-	-	15,333	chief medical officer

Which funds bought or sold SYRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	unchanged	-	-6,112,180	13,401,800	0.34%
May 16, 2024	JANE STREET GROUP, LLC	added	716	758,324	922,966	-%
May 15, 2024	Bain Capital Life Sciences Investors, LLC	unchanged	-	-6,709,530	14,711,500	1.18%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-283,899	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	61,792	61,792	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	85,793	85,793	-%
May 15, 2024	Blue Owl Capital Holdings LP	reduced	-77.17	-6,639,000	1,823,570	0.36%
May 15, 2024	Opaleye Management Inc.	added	119	1,413,340	4,212,830	0.96%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	48,150	48,150	-%
May 15, 2024	Man Group plc	new	-	242,323	242,323	-%

Are Funds Buying or Selling SYRS?

Are funds buying SYRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SYRS

No. of Funds

Unveiling Syros Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	5.74%	1,493,252	SC 13G
Feb 13, 2024	ally bridge medalpha master fund l.p.	2.6%	570,976	SC 13G/A
Feb 13, 2024	bain capital life sciences fund ii, l.p.	9.99%	2,749,808	SC 13G/A
Feb 13, 2024	avidity partners management lp	9.9%	2,662,206	SC 13G/A
Feb 09, 2024	artal international s.c.a.	9.9%	3,568,842	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	9.99%	2,623,984	SC 13G/A
Jan 02, 2024	point72 asset management, l.p.	5.7%	1,471,771	SC 13G
Dec 26, 2023	samsara biocapital, l.p.	9.5%	2,493,541	SC 13D/A
Oct 20, 2023	samsara biocapital, l.p.	7.4%	1,588,564	SC 13D
Feb 14, 2023	bain capital life sciences fund ii, l.p.	9.99%	2,124,694	SC 13G/A

Recent SEC filings of Syros Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Syros Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Syros Pharmaceuticals Inc News

Latest updates

Syros Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-89.7%	387	3,762	2,833	2,954	3,423	3,891	6,276	5,467	7,802	5,697	5,162	4,827	5,698	3,828	3,188	2,379	508	558	462	454	893
Operating Expenses	-28.3%	27,527	38,398	36,833	36,166	35,243	43,345	40,045	32,120	33,226	32,608	31,306	25,768	34,918	22,825	19,929	19,718	20,679	20,947	20,670	17,427	19,500
S&GA Expenses	-24.2%	5,888	7,764	7,225	7,405	7,329	8,076	6,945	6,949	6,431	5,346	5,520	5,739	5,892	5,151	5,133	5,149	6,402	5,016	5,195	4,865	4,372
R&D Expenses	-24.0%	21,504	28,280	29,608	28,761	27,914	25,759	33,100	25,171	26,795	27,262	25,786	20,029	29,026	17,674	14,796	14,569	14,277	15,931	15,475	12,562	15,128
Interest Expenses	2.0%	1,329	1,303	1,278	1,217	1,126	1,051	981	976	987	984	969	967	541	493	487	271	20.00	21.00	23.00	8.00	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	-	-	-	-	-
Net Income	-60.4%	-64,384	-40,143	-36,258	-23,789	-4,774	-30,253	-34,481	-25,146	-23,813	-26,027	-22,490	-14,228	-30,130	-19,486	-17,196	-17,226	-19,729	-19,793	-19,455	-16,461	-18,032
Net Income Margin	-76.3%	-16.56*	-9.40*	-7.66*	-6.84*	-6.36*	-4.85*	-4.34*	-4.04*	-3.69*	-4.34*	-4.42*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	41.6%	-18,600	-31,858	-22,385	-37,136	-31,757	-36,115	-26,289	-30,145	-23,214	-28,437	-26,882	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.9%	135	168	148	181	205	244	285	126	152	183	208	234	110	213	133	148	161	150	144	152	88.00
Current Assets	-22.6%	112	145	123	153	174	211	252	92.00	116	137	153	186	110	179	99.00	112	126	115	111	124	78.00
Cash Equivalents	-38.6%	86.00	140	112	115	105	167	15.00	59.00	70.00	95.00	119	164	225	174	93.00	109	117	45.00	33.00	102	22.00
Net PPE	-4.6%	7.00	7.00	8.00	10.00	11.00	11.00	12.00	12.00	13.00	13.00	13.00	14.00	14.00	14.00	15.00	15.00	16.00	15.00	11.00	5.00	4.00
Current Liabilities	1.7%	37.00	37.00	28.00	28.00	24.00	31.00	38.00	39.00	28.00	32.00	30.00	28.00	6.00	29.00	28.00	23.00	20.00	24.00	23.00	15.00	15.00
Long Term Debt	-14.0%	30.00	35.00	39.00	41.00	39.00	41.00	41.00	34.00	39.00	40.00	40.00	40.00	40.00	40.00	20.00	20.00	20.00	-	-	-	-
LT Debt, Current	75.0%	12.00	7.00	2.00	-	2.00	-	-	7.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	35.00	39.00	41.00	39.00	41.00	41.00	34.00	39.00	40.00	40.00	40.00	40.00	40.00	20.00	20.00	20.00	-	-	-	-
Shareholder's Equity	-9.6%	15.00	17.00	36.00	73.00	107	128	129	31.00	63.00	85.00	106	130	150	91.00	46.00	62.00	19.00	79.00	95.00	112	64.00
Retained Earnings	-0.5%	-726	-722	-658	-618	-582	-558	-553	-523	-488	-463	-439	-413	-136	-377	-346	-327	-310	-292	-273	-253	-234
Additional Paid-In Capital	0.3%	742	739	695	691	688	686	683	554	552	549	546	544	239	468	393	390	387	372	368	365	298
Shares Outstanding	1.1%	27.00	26.00	21.00	21.00	20.00	20.00	9.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	59.00	-	-	-	56.00	-	-	-	311	-	-	-	442,689	-	-	-	351,070	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-67.5%	-31,098	-18,562	-31,858	-22,386	-36,901	-31,083	-35,787	-26,178	-30,017	-22,969	-28,127	-26,454	-21,990	-29,924	-15,255	-12,431	246	-10,603	-11,224	-18,099	-20,327
Share Based Compensation	22.3%	2,103	1,720	3,255	2,814	2,645	2,903	2,955	2,689	2,863	2,875	2,096	2,453	2,930	3,030	2,723	2,727	2,459	3,216	2,389	2,355	1,879
Cashflow From Investing	-1718.9%	-24,640	1,522	28,640	32,923	-25,748	37,721	6,192	15,889	7,383	-245	-17,301	-34,845	-262	-29.00	-522	4,012	43,203	16,953	-57,140	32,682	-4,229
Cashflow From Financing	-100.6%	-265	43,380	-5.00	140	-53.00	-10,703	142,064	-223	-93.00	96.00	-67.00	72.00	70,410	110,804	236	220	31,693	1,089	-12.00	65,028	-115

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SYRS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue		$ 2,954
Operating expenses:
Research and development	$ 24,655	28,761
General and administrative	6,266	7,405
Total operating expenses	30,921	36,166
Loss from operations	(30,921)	(33,212)
Interest income	1,546	1,775
Interest expense	(1,307)	(1,217)
Change in fair value of warrant liabilities	26,974	8,865
Net loss applicable to common stockholders	$ (3,708)	$ (23,789)
Net loss per share applicable to common stockholders - basic	$ (0.1)	$ (0.85)
Net loss per share applicable to common stockholders - diluted	$ (0.1)	$ (0.85)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic	38,978,046	27,842,218
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted	38,978,046	27,842,218

SYRS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 83,523	$ 139,526
Marketable securities	24,781
Prepaid expenses and other current assets	3,898	5,454
Total current assets	112,202	144,980
Property and equipment, net	6,964	7,298
Other long-term assets	1,550	1,592
Restricted cash	2,119	2,119
Right-of-use asset – operating lease	11,893	12,185
Total assets	134,728	168,174
Current liabilities:
Accounts payable	11,346	11,544
Accrued expenses	11,881	16,146
Operating lease obligation, current portion	2,409	2,324
Debt, current portion	11,667	6,667
Total current liabilities	37,303	36,681
Operating lease obligation, net of current portion	17,887	18,528
Warrant liabilities	34,773	61,747
Debt, net of debt discount, net of current portion	29,708	34,556
Commitments and contingencies (See Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 70,000,000 shares authorized at March 31, 2024 and December 31, 2023; 26,728,337 and 26,448,678 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	26	26
Additional paid-in capital	741,546	739,443
Accumulated deficit	(726,515)	(722,807)
Total stockholders' equity	15,057	16,662
Total liabilities and stockholders' equity	$ 134,728	$ 168,174

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Nancy A. Simonian M.D.
WEBSITE	syros.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Syros Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syros Pharmaceuticals Inc? What does SYRS stand for in stocks?

SYRS is the stock ticker symbol of Syros Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syros Pharmaceuticals Inc (SYRS)?

As of Fri May 17 2024, market cap of Syros Pharmaceuticals Inc is 145.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers. The fair value of Syros Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syros Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syros Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SYRS is over valued or under valued. Whether Syros Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syros Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYRS.

What is Syros Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SYRS's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 14.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYRS PE ratio will change depending on the future growth rate expectations of investors.